Youngman Angis Oh from 5305 Hillshire Way, Glen Allen, VA 23059, age 68, Phone: (804)3649892

Us Patents

Mutant Igfbp-3 Molecules That Do Not Bind To Igfs, But Retain Their Ability To Functionally Bind Igfbp-3 Receptor
view source
US Patent:

7514532, Apr 7, 2009
Filed:

Mar 7, 2007
Appl. No.:

11/715600
Inventors:

Youngman Oh - Glen Allen VA, US
Ron G. Rosenfeld - Los Altos CA, US
Caroline K. Buckway - Stanford CA, US
Assignee:

Oregon Health & Science University - Portland OR
International Classification:

A61K 38/00
US Classification:

530324, 530350
Abstract:

There is disclosed novel mutant IGFBP-3 polypeptides and fragments thereof that have either no binding, or diminished binding to IGFs, yet retain their ability to bind to the human IGFBP-3 receptor (“P4. 33”). The present invention provides novel mutant IGFBP-3 nucleic acid sequences, and expression systems. Additional embodiments provide for screening assays for identifying IGFBP-3 receptor antagonists or agonists, methods for modulating IGF-independent IGFBP-3 responses of cells expressing IGFBP-3 receptors, A methods for inducing or potentiating apoptosis of cells expressing IGFBP-3 receptors, methods for treating solid tumors having cells expressing IGFBP-3 receptors, and compositions comprising polypeptides having either no binding, or diminished binding to IGFs, yet retain their ability to bind to the IGFBP-3 receptor.

Induction Of Apoptosis And Cell Growth Inhibition By Protein 4.33
view source
US Patent:

7585497, Sep 8, 2009
Filed:

May 17, 2001
Appl. No.:

10/276491
Inventors:

Youngman Oh - Richmond VA, US
Ron Rosenfeld - Palo Alto CA, US
Angela Renae Ingermann - Beaverton OR, US
Assignee:

Oregon Health & Science University - Portland OR
International Classification:

A01N 43/04
A01N 63/00
A61K 31/715
US Classification:

424 932, 514 44
Abstract:

There is disclosed an isolated cDNA sequence (SEQ ID NO:1) encoding a P4. 33 polypeptide and comprising a coding region (SEQ ID NO:2) of the sequence described in SEQ ID NO:1, or a sequence having at least 90% homology with the coding region of SEQ ID NO:1. The P4. 33 polypeptide functions as a specific cell-surface receptor for IGFBP-3, and undergoes nuclear translocation in combination with IGFBP-3. IGFBP-3 and P4. 33 (IGFBP-3R) cooperatively suppress DNA synthesis and cell growth, and induce caspase activation and apoptosis in cancer cells, indicating that P4. 33 is an important mediator of IGF-independent growth inhibitory actions of IGFBP-3. The P4. 33:IGFBP-3 system of the present invention can be used, inter alia, in screening and diagnostic assays, and for therapeutic methods for cancer treatment and tumor suppression.

Mutant Igfbp-3 Molecules That Do Not Bind To Igfs, But Retain Their Ability To Functionally Bind Igfbp-3 Receptor
view source
US Patent:

7714102, May 11, 2010
Filed:

Feb 11, 2009
Appl. No.:

12/369268
Inventors:

Youngman Oh - Glen Allen VA, US
Ron G. Rosenfeld - Los Altos CA, US
Caroline K. Buckway - Mountain View CA, US
Assignee:

Oregon Health & Science University - Portland OR
International Classification:

A61K 38/00
US Classification:

530324, 530350
Abstract:

There is disclosed novel mutant IGFBP-3 polypeptides and fragments thereof that have either no binding, or diminished binding to IGFs, yet retain their ability to bind to the human IGFBP-3 receptor (“P4. 33”). The present invention provides novel mutant IGFBP-3 nucleic acid sequences, and expression systems. Additional exemplary embodiments provide for screening assays for identifying IGFBP-3 receptor antagonists or agonists, methods for modulating IGF-independent IGFBP-3 responses of cells expressing IGFBP-3 receptors, methods for inducing or potentiating apoptosis of cells expressing IGFBP-3 receptors, methods for treating solid tumors having cells expressing IGFBP-3 receptors, and compositions comprising polypeptides having either no binding, or diminished binding to IGFs, yet retain their ability to bind to the IGFBP-3 receptor.

Novel Mutant Igbp-3 Molecules That Do Not Bind To Igfs, But Retain Their Ability To Functionally Bind Igfbp-3 Receptor
view source
US Patent:

20050069873, Mar 31, 2005
Filed:

Oct 29, 2001
Appl. No.:

10/415398
Inventors:

Youngman Oh - Beaverton OR, US
Ron Rosenfeld - Los Altos CA, US
Caroline Buckway - Tualatin OR, US
International Classification:

C12Q001/68
G01N033/53
C07H021/04
C07K014/71
US Classification:

435006000, 435069100, 435320100, 435325000, 530350000, 536023500, 435007100
Abstract:

There is disclosed movel mutant IGFBP-3 polypeptides and fragments thereof that have either no binding, or diminished binding to IGFs, yet retain their ability to bind to the human IGFBP-3 receptor (“P4.33”). The present invention provides novel mutant IGFBP-3 nucleic acid sequences, and expression systems. Additional embodiments provide for screening assays for identifying IGFBP-3 receptor antagonists or agonists, methods for modulating IGF-independent IGFBP-3 responses of cells expressing IGFBP-3 receptors, A methods for inducing or potentiating apoptosis of cells expressing IGFBP-3 receptors, methods for treating solid tumors having cells expressing IGFBP-3 receptors, and compositions comprising polypeptides having either no binding, or diminished binding to IGFs, yet retain their ability to bind to the IGFBP-3 receptor.

Methods And Compositions For Treatment Or Prevention Of Radiation-Induced Fibrosis
view source
US Patent:

20090069623, Mar 12, 2009
Filed:

Aug 21, 2008
Appl. No.:

12/195845
Inventors:

YOUNGMAN OH - Glen Allen VA, US
Assignee:

Virginia Commonwealth University Intellectual Property Foundation - Richmond VA
International Classification:

A61B 6/00
A61K 31/404
A61K 31/366
A61K 31/40
A61K 31/435
A61K 31/47
A61K 39/395
A61K 38/00
A61K 31/7088
US Classification:

600 1, 514419, 514460, 514423, 514277, 514311, 4241721, 4241331, 514 2, 514 44
Abstract:

The present invention comprises methods and compositions for the treatment or prevention of radiation-induced fibrosis. Methods and compositions for the inhibition of CTGF are disclosed herein. Methods and compositions for treatment of neoplastic disease are disclosed herein. Inhibition of CTGF in humans or animals that have been exposed to ionizing radiation results in treatment or prevention of radiation-induced fibrosis.

Induction Of Apoptosis And Cell Growth Inhibition By Protein 4.33
view source
US Patent:

20100120143, May 13, 2010
Filed:

Jun 4, 2009
Appl. No.:

12/478599
Inventors:

Youngman Oh - Glen Allen VA, US
Ron G. Rosenfeld - Los Altos CA, US
Angela Ranae Ingermann - Beaverton OR, US
Assignee:

Oregon Health & Science University - Portland OR
International Classification:

C12N 5/10
C07H 21/04
C12N 15/63
C07K 14/47
C07K 16/00
US Classification:

435366, 536 235, 4353201, 530350, 5303879
Abstract:

There is disclosed an isolated cDNA sequence (SEQ ID NO:1) encoding a P4.33 polypeptide and comprising a coding region (SEQ ID NO:2) of the sequence described in SEQ ID NO:1, or a sequence having at least 90% homology with the coding region of SEQ ID NO:1. The P4.33 polypeptide functions as a specific cell-surface receptor for IGFBP-3, and undergoes nuclear translocation in combination with IGFBP-3. In particular aspects, IGFBP-3 and P4.33 (IGFBP-3R) cooperatively suppress DNA synthesis and cell growth, and induce caspase activation and apoptosis in cancer cells, indicating that P4.33 is an important mediator of IGF-independent growth inhibitory actions of IGFBP-3. The P4.33:IGFBP-3 system of the present invention can be used, inter alia, in screening and diagnostic assays, and for therapeutic methods for cancer treatment and tumor suppression.

Methods And Compositions For Treatment Of Tumor Metastasis
view source
US Patent:

20120156216, Jun 21, 2012
Filed:

Mar 2, 2010
Appl. No.:

13/254709
Inventors:

Youngman OH - Glen Allen VA, US
International Classification:

A61K 39/395
A61K 31/366
C07D 309/30
A61K 31/22
A61P 35/04
C07K 16/18
A61K 31/59
A61K 31/375
G01N 33/574
C07K 16/22
C07C 69/013
US Classification:

4241581, 4241721, 5303892, 514460, 549292, 514546, 560256, 5303891, 514167, 514474, 436501
Abstract:

The various embodiments of the present invention are directed to methods and compositions for treatment, inhibition or reduction of metastasis in cancers. In particular, the invention is related to compositions and methods affecting connective tissue growth factor (CTGF). An aspect of the present invention comprises a method for interfering with the activity of connective tissue growth factor, comprising, administering to a subject an effective amount of a composition that inhibits production of or activity of connective tissue growth factor (CTGF), wherein the composition interferes with the activity of CTGF or prevents the transcription of CTGF genes or translation of CTGF mRNA. For example, the composition can comprises at least one HMG-CoA reductase inhibitor compound, such as a statin.

Diagnosis And Therapy Of Chronic Inflammation-Induced Disorders
view source
US Patent:

20160011207, Jan 14, 2016
Filed:

Dec 5, 2013
Appl. No.:

14/648802
Inventors:

- Richmond VA, US
Youngman OH - Richmond VA, US
International Classification:

G01N 33/68
C07K 7/06
Abstract:

Methods and compositions for the diagnosis and treatment of chronic inflammation (obesity)-induced disorders such as insulin resistance, diabetes, cancer and various metabolic disorders, are provided. The methods and compositions detect both full-blown disease and early stage disease by detecting proteolysis, by neutrophil proteases, of insulin-like growth factor binding protein-3 (IGFBP3). Levels of proteolytic fragments of IGFBP3 and/or levels of intact IGFPB-3 and/or levels/activity neutrophil proteases are detected. Agents (e.g. peptide agents) that inhibit the proteolysis of IGFPB-3 and methods of using the agents to prevent and treat chronic inflammation (obesity)-induced disorders are also provided.